VERVE Enrollment Criteria

• Age > 50 years
• Current use of a TNF inhibitor (for any indication)
• No previous vaccination with Zostavax®
• Systemic glucocorticoid use (up to 10 mg prednisone per day) allowed
• Must have lived in the US for at least 30 years; or have a past history of Chicken Pox
• Visit the VERVE study at ClinicalTrials.gov “A service of the U.S. National Institutes of Health”

Interested in joining the VERVE team? Contact the UAB VERVE Study at (205) 934-2993 or email verve@uab.edu